An investigation for investors in Raptor Pharmaceutical Corp. (NASDAQ:RPTP) shares over potential securities laws violations by Raptor Pharmaceutical was announced and NASDAQ:RPTP stockholders should contact the Shareholders Foundation.
San Diego, CA -- (SBWIRE) -- 10/06/2015 -- An investigation for shareholders in NASDAQ:RPTP shares over potential securities laws violations by Raptor Pharmaceutical in connection certain financial statements was announced.
Investors who purchased shares of Raptor Pharmaceutical Corp. (NASDAQ:RPTP), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation or call 858-779-1554.
The investigation by a law firm focuses on possible claims on behalf of purchasers of the securities of Raptor Pharmaceutical Corp. (NASDAQ:RPTP) concerning whether a series of statements by Raptor Pharmaceutical regarding its business, its prospects and its operations were materially false and misleading at the time they were made.
On September 14, 2015, pre-market, Raptor Pharmaceutical Corp reported that RP103, its product candidate for treatment of nonalcoholic steatohepatitis (NASH) in adolescents, failed to achieve its primary endpoint in a Phase IIb study and that based on the results, Raptor Pharmaceutical Corp will cease development of RP103 for NASH.
Shares of Raptor Pharmaceutical Corp. (NASDAQ:RPTP) declined to as low as $6.82 per share on September 14, 2015.
On October 5, 2015, NASDAQ:RPTP shares closed at $6.05 per share
Those who purchased NASDAQ:RPTP shares have certain options and should contact the Shareholders Foundation.
Contact:
Shareholders Foundation, Inc.
Michael Daniels
3111 Camino Del Rio North - Suite 423
92108 San Diego
Phone: +1-(858)-779-1554
Fax: +1-(858)-605-5739
mail@shareholdersfoundation.com